"More Americans than ever are developing kidney stones, and the demographics of those at increased risk are changing, a study published online January 14 in the Clinical Journal of the American Society of Nephrology has shown.
Some patients may develop minor gastrointestinal complaints during Urocit®-K (potassium citrate extended-release tablets) therapy, such as abdominal discomfort, vomiting, diarrhea, loose bowel movements or nausea. These symptoms are due to the irritation of the gastrointestinal tract, and may be alleviated by taking the dose with meals or snacks, or by reducing the dosage. Patients may find intact matrices in their feces.
Read the Urocit-K (potassium citrate extended-release tablets) Side Effects Center for a complete guide to possible side effects
Potential Effects of Potassium citrate on Other Drugs
Concomitant administration of Urocit®-K (potassium citrate extended-release tablets) and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia.
Potential Effects of Other Drugs on Potassium citrate
Drugs that slow gastrointestinal transit time
These agents (such as anticholinergics) can be expected to increase the gastrointestinal irritation produced by potassium salts.
Read the Urocit-K Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 1/21/2010
Additional Urocit-K Information
Urocit-K - User Reviews
Urocit-K User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.